Table II.
Hazards ratio obtained from Cox model
| Crude HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value | |
|---|---|---|---|---|
| Treatment | < 10–4 | < 10–4 | ||
| TNF inhibitors | Ref | Ref | Ref | Ref |
| Ustekinumab | 0.40 (0.32–0.51) | < 10–4 | 0.42 (0.32–0.56) | < 10–4 |
| IL17 inhibitors | 0.47 (0.27–0.83) | 0.009 | 0.36 (0.18–0.71) | 0.004 |
| Apremilast | 3.42 (2.77–4.21) | < 10–4 | 3.60 (2.67–4.83) | < 10–4 |
| Year of initiation | 0.06 | 0.63 | ||
| 2012 | Ref | Ref | ||
| 2013 | 0.67 (0.41–1.09) | 0.80 (0.42–1.52) | ||
| 2014 | 0.79 (0.49–1.25) | 1.03 (0.56–1.90) | ||
| 2015 | 0.71 (0.45–1.13) | 0.98 (0.53–1.81) | ||
| 2016 | 0.88 (0.55–1.40) | 1.17 (0.64–2.17) | ||
| 2017 | 1.02 (0.65–1.60) | 1.04 (0.56–1.94) | ||
| 2018 | 0.78 (0.48–1.24) | 0.97 (0.51–1.83) | ||
| Sex (Female) | 1.51 (1.28–1.78) | < 10–4 | 1.31 (1.08–1.58) | 0.007 |
| PsA | 1.09 (0.89–1.34) | 0.39 | 0.92 (0.72–1.18) | 0.50 |
| Age, years | 1.01 (1.00–1.02) | 0.007 | 1.00 (0.99–1.01) | 0.35 |
| Body mass index, kg/m2 | 0.003 | 0.036 | ||
| < 25 | Ref | Ref | Ref | Ref |
| 25–30 | 1.22 (0.98–1.51) | 0.07 | 1.22 (0.96–1.54) | 0.10 |
| > 30 | 1.45 (1.17–1.79) | 0.0006 | 1.36 (1.07–1.73) | 0.011 |
| Comorbidities | ||||
| 0 | Ref | Ref | Ref | Ref |
| 1 + | 1.18 (0.99–1.41) | 0.07 | 1.11 (0.89–1.38) | 0.33 |
| Positive TB screening | 0.74 (0.51–1.08) | 0.12 | 0.72 (0.46–1.12) | 0.15 |
| Concomitant MTX at baseline | 1.43 (1.14–1.79) | 0.002 | 1.25 (0.94–1.66) | 0.12 |
| Previous MTX use | 1.17 (0.99–1.39) | 0.06 | 1.10 (0.90–1.35) | 0.34 |
| Previous cyclosporine use | 1.14 (0.90–1.43) | 0.26 | 1.20 (0.91–1.58) | 0.19 |
| Previous PUVA therapy | 0.90 (0.76–1.06) | 0.22 | 1.08 (0.88–1.33) | 0.52 |
| PASI at baseline | 1.00 (0.99–1.01) | 0.26 | 1.01 (0.99–1.02) | 0.15 |
HR: hazard ratio; MTX: methotrexate; PsA: psoriasis arthritis; PUVA: psoralen plus ultraviolet A; TNF: tumour necrosis factor; IL-17: interleukin-17; TB: tuberculosis; PASI: Psoriasis Area and Severity Index. Bold: p-value < 0.05.